 Siobhan Proksell
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 10 | 2025 | 260 | 2.000 |
Why?
| | Colitis, Ulcerative | 7 | 2025 | 148 | 1.590 |
Why?
| | Inflammatory Bowel Diseases | 10 | 2025 | 364 | 1.560 |
Why?
| | Weight Loss | 2 | 2023 | 858 | 0.390 |
Why?
| | Pancreatic Diseases | 1 | 2013 | 66 | 0.390 |
Why?
| | Diarrhea | 1 | 2013 | 193 | 0.370 |
Why?
| | Internship and Residency | 1 | 2020 | 1267 | 0.300 |
Why?
| | Intestinal Mucosa | 3 | 2025 | 675 | 0.290 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 767 | 0.280 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2187 | 0.270 |
Why?
| | Feces | 3 | 2025 | 495 | 0.260 |
Why?
| | Adenocarcinoma | 3 | 2021 | 925 | 0.250 |
Why?
| | Dual Oxidases | 1 | 2025 | 4 | 0.230 |
Why?
| | Bacterial Translocation | 1 | 2025 | 52 | 0.220 |
Why?
| | Leukopenia | 1 | 2024 | 33 | 0.210 |
Why?
| | Phagocytes | 1 | 2025 | 80 | 0.210 |
Why?
| | Pyrophosphatases | 1 | 2024 | 26 | 0.210 |
Why?
| | Stromal Cells | 1 | 2024 | 121 | 0.200 |
Why?
| | Dysbiosis | 1 | 2025 | 187 | 0.200 |
Why?
| | Caloric Restriction | 1 | 2025 | 133 | 0.200 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2930 | 0.200 |
Why?
| | Physical Examination | 1 | 2023 | 243 | 0.170 |
Why?
| | Cholangitis, Sclerosing | 1 | 2021 | 61 | 0.160 |
Why?
| | Flow Cytometry | 1 | 2024 | 1162 | 0.160 |
Why?
| | Colorectal Neoplasms | 2 | 2021 | 866 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2021 | 166 | 0.150 |
Why?
| | Environmental Exposure | 1 | 2024 | 578 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 254 | 0.140 |
Why?
| | C-Reactive Protein | 2 | 2025 | 422 | 0.140 |
Why?
| | Eosinophilia | 1 | 2020 | 223 | 0.140 |
Why?
| | Adult | 14 | 2025 | 40777 | 0.140 |
Why?
| | Humans | 22 | 2025 | 145475 | 0.130 |
Why?
| | Colonic Neoplasms | 1 | 2020 | 257 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 198 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 1188 | 0.130 |
Why?
| | Counseling | 1 | 2020 | 400 | 0.130 |
Why?
| | Inflammation | 2 | 2025 | 2878 | 0.120 |
Why?
| | Male | 18 | 2025 | 72843 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2021 | 892 | 0.120 |
Why?
| | Middle Aged | 13 | 2025 | 36215 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2769 | 0.110 |
Why?
| | Colonoscopy | 1 | 2018 | 263 | 0.110 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 104 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 530 | 0.110 |
Why?
| | Polyomavirus | 1 | 2014 | 11 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 881 | 0.110 |
Why?
| | Polyomavirus Infections | 1 | 2014 | 30 | 0.110 |
Why?
| | Young Adult | 7 | 2025 | 14219 | 0.110 |
Why?
| | Tumor Virus Infections | 1 | 2014 | 51 | 0.110 |
Why?
| | Female | 15 | 2025 | 78845 | 0.100 |
Why?
| | Radiography, Abdominal | 1 | 2013 | 44 | 0.100 |
Why?
| | Aged | 8 | 2025 | 26153 | 0.100 |
Why?
| | Curriculum | 1 | 2020 | 1070 | 0.100 |
Why?
| | Psychotropic Drugs | 1 | 2014 | 78 | 0.100 |
Why?
| | Risk Factors | 4 | 2024 | 10885 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2018 | 1217 | 0.100 |
Why?
| | Pelvis | 1 | 2013 | 125 | 0.090 |
Why?
| | Transplant Recipients | 1 | 2014 | 181 | 0.090 |
Why?
| | Colon | 2 | 2024 | 309 | 0.090 |
Why?
| | Sarcoidosis | 1 | 2013 | 163 | 0.080 |
Why?
| | Depressive Disorder | 1 | 2014 | 374 | 0.080 |
Why?
| | Cholestasis | 1 | 2013 | 214 | 0.080 |
Why?
| | Biomarkers | 4 | 2024 | 4295 | 0.080 |
Why?
| | Liver Diseases | 1 | 2013 | 305 | 0.080 |
Why?
| | Hospitalization | 2 | 2020 | 2460 | 0.070 |
Why?
| | Registries | 3 | 2022 | 2406 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 8057 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2025 | 3623 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 826 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2588 | 0.060 |
Why?
| | Disease Progression | 1 | 2013 | 2864 | 0.060 |
Why?
| | Serum Amyloid A Protein | 1 | 2025 | 32 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2025 | 41 | 0.060 |
Why?
| | Permeability | 1 | 2025 | 169 | 0.050 |
Why?
| | Faecalibacterium | 1 | 2024 | 1 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2024 | 17 | 0.050 |
Why?
| | Indians, South American | 1 | 2024 | 23 | 0.050 |
Why?
| | Dietary Fiber | 1 | 2024 | 59 | 0.050 |
Why?
| | Ileum | 1 | 2025 | 112 | 0.050 |
Why?
| | Methyltransferases | 1 | 2024 | 75 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3922 | 0.050 |
Why?
| | Alaska Natives | 1 | 2024 | 97 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2024 | 175 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 499 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 480 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1082 | 0.040 |
Why?
| | Escherichia coli | 1 | 2025 | 835 | 0.040 |
Why?
| | Mesalamine | 1 | 2020 | 9 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2013 | 2970 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 118 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1891 | 0.040 |
Why?
| | Cohort Studies | 2 | 2024 | 6013 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2024 | 870 | 0.040 |
Why?
| | Bacteria | 1 | 2024 | 765 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 555 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3204 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2021 | 777 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2020 | 260 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8333 | 0.030 |
Why?
| | Adolescent | 3 | 2024 | 22530 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2024 | 17291 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6066 | 0.030 |
Why?
| | Biological Products | 1 | 2020 | 257 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 635 | 0.030 |
Why?
| | Diet | 1 | 2024 | 1277 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3342 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2378 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4560 | 0.030 |
Why?
| | Histocytochemistry | 1 | 2014 | 78 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2014 | 156 | 0.030 |
Why?
| | Blood | 1 | 2014 | 107 | 0.030 |
Why?
| | Exanthema | 1 | 2014 | 86 | 0.030 |
Why?
| | Viremia | 1 | 2014 | 160 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 881 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2865 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2013 | 106 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 969 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2014 | 202 | 0.020 |
Why?
| | Colectomy | 1 | 2013 | 106 | 0.020 |
Why?
| | Radiotherapy | 1 | 2013 | 204 | 0.020 |
Why?
| | Fluorouracil | 1 | 2013 | 231 | 0.020 |
Why?
| | Child | 2 | 2024 | 22707 | 0.020 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2013 | 98 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1547 | 0.020 |
Why?
| | Regression Analysis | 1 | 2014 | 1001 | 0.020 |
Why?
| | Endoscopy | 1 | 2014 | 317 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1266 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1716 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1327 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11772 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4075 | 0.020 |
Why?
| | Skin | 1 | 2014 | 753 | 0.020 |
Why?
| | Child, Preschool | 1 | 2024 | 11853 | 0.020 |
Why?
| | Mice | 1 | 2025 | 18329 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 2105 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2923 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5423 | 0.010 |
Why?
| | Animals | 1 | 2025 | 38030 | 0.010 |
Why?
|
|
Proksell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|